Evidence map›Paper›PMID 35891147›Full record

ArticleVaccines2022

Assessment of In Vitro Immunostimulatory Activity of an Adjuvanted Whole-Cell Inactivated

Priyal Bagwe, Lotika Bajaj, Rikhav P Gala, Martin J D'Souza, Susu M Zughaier

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Priyal BagweVaccine Nanotechnology Laboratory, Center for Drug Delivery Research, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA.ORCID 0000-0001-7151-5018
Lotika BajajVaccine Nanotechnology Laboratory, Center for Drug Delivery Research, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA.
Rikhav P GalaFraunhofer USA, Center Mid-Atlantic, Biotechnology Division, 9, Innovation Way, Newark, DE 19011, USA.ORCID 0000-0003-2789-5804
Martin J D'SouzaVaccine Nanotechnology Laboratory, Center for Drug Delivery Research, College of Pharmacy, Mercer University, Atlanta, GA 30341, USA.
Susu M ZughaierDepartment of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha P.O. Box 2731, Qatar.ORCID 0000-0001-7487-8770
Mercer University · USFraunhofer USA · USQatar University · QA

Funding

Whole cell Neisseria gonorrhoeae micro particulate vaccineR15AI133473 · NIAID · MERCER UNIVERSITY MACON · PI D'SOUZA, MARTIN J. · 2018 to 2018
$463k
National Institute of Health 1R15AI133473-01A1NIAID NIH HHS R15 AI133473
6 · The paper itself

Abstract

The emergence of drug-resistant gonorrhea infections worldwide combined with the lack of a vaccine is alarming. We prepared a novel microparticulate (MP) vaccine formulation using whole-cell inactivated

Indexed as

antigen presentationautophagygonorrheamicroparticlesNeisseria gonorrhoeaevaccines

Identifiers

PMID35891147
PMCPMC9320116
OpenAlexW4283313333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.